WASHINGTON, DC (September 6, 2011) – The ALS Association applauds the proposed agreement for the reauthorization of the Prescription Drug User Fee Act (PDUFA), which includes provisions that would help to encourage and expedite the approval of new treatments for rare diseases like ALS, also known as Lou Gehrig’s Disease. The proposed agreement was released by the Food and Drug Administration (FDA) on September 1.
PDUFA authorizes the FDA to collect fees from companies that develop drugs and biologic products. These fees help the agency cover the costs of drug reviews and currently account for about half of the agency’s drug review costs. The law originally was established in 1992 and has been reauthorized every five years since that time. The current law expires next year unless it is reauthorized by September 30, 2012.
“The reauthorization of PDUFA is critical to discovering a treatment and cure for ALS,” said Jane Gilbert, President and CEO of The ALS Association. “There is no effective treatment for ALS and it is fatal in an average of just two to five years. By providing the agency with the resources it needs to review new treatments and ensure their efficacy and safety, PDUFA helps to make sure that funding limitations do not block innovative treatments from reaching the patients who so urgently need them.”
“The additional resources and the establishment of drug review timeframes are important elements of PDUFA,” said Steve Gibson, The ALS Association’s Chief Public Policy Officer. “This proposal is particularly significant because it was developed with the input of the patient community in partnership with the FDA and industry. And it is significant because it includes key provisions that promote the development of new treatments and recognize that the practice of medicine is not a one-size-fits-all proposition, especially when it comes to a disease like Lou Gehrig’s Disease.”
Since July 2010, The ALS Association participated in monthly meetings with FDA officials to bring the perspective of people with ALS to the discussion on the reauthorization of PDUFA. Three key provisions advocated by The Association were included in the proposed agreement. They include:
“Congress has authorized PDUFA four times beginning in 1992. But perhaps no other version of the law is as important to people with ALS as PDUFA V,” said Gibson. “Right now people with ALS have no way to defend themselves in the fight against the disease. It will take their lives. But PDUFA V can help them fight back. It promotes new treatments. It speeds access. And it makes sense. We urge Congress to swiftly adopt the PDUFA V proposal in 2012.”
The proposed agreement released by the FDA is available on the FDA website here: http://www.fda.gov/downloads/ForIndustry/UserFees/PrescriptionDrugUserFee/UCM270412.pdf.
The ALS Association is the only non-profit organization fighting Lou Gehrig’s Disease on every front. By leading the way in global research, providing assistance for people with ALS through a nationwide network of chapters, coordinating multidisciplinary care through certified clinical care centers, and fostering government partnerships, The Association builds hope and enhances quality of life while aggressively searching for new treatments and a cure.
For more information about The ALS Association, visit www.alsa.org or call 800-782-4747.